Company Description
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies.
Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer.
The company’s LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma.
The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute.
Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
| Country | United States |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Geordan Pursglove |
Contact Details
Address: 680 East Colorado Boulevard, Suite 180 Pasadena, California 91101 United States | |
| Phone | 631 830 7092 |
| Website | lixte.com |
Stock Details
| Ticker Symbol | LIXT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001335105 |
| CUSIP Number | 539319202 |
| ISIN Number | US5393193017 |
| Employer ID | 20-2903526 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Geordan G. Pursglove | Chief Executive Officer and Chairman |
| Bastiaan van der Baan M.Sc. | President and Chief Scientific Officer |
| Peter M. Stazzone | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 11, 2025 | 8-K | Current Report |
| Sep 4, 2025 | 8-K | Current Report |
| Aug 19, 2025 | 8-K | Current Report |
| Aug 14, 2025 | 8-K | Current Report |
| Aug 7, 2025 | UPLOAD | Filing |
| Aug 7, 2025 | 10-Q | Quarterly Report |
| Jul 21, 2025 | 8-K | Current Report |
| Jul 16, 2025 | UPLOAD | Filing |
| Jul 16, 2025 | 8-K | Current Report |
| Jul 15, 2025 | EFFECT | Notice of Effectiveness |